Concepedia

Author

Leif Stenke

Karolinska University HospitalORCID

Also Known As

J. L. Steegmann, Joaquin Martinez-Lopez, Joaquín Martínez-López, L Stenke, L. STENKE, L. Stenke, L.Å.L. Stenke, LEIF STENKE, Leif Pr Stenke, Leif STENKE

219

Publications

6.5K

Citations

38

H-Index

75

Concepts

All Affiliations

Karolinska University HospitalKarolinska InstitutetUppsala University HospitalUmeå UniversitySkåne University Hospital
LS

About

Leif Stenke is an author at Karolinska University Hospital specializing in medicine, hematology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

31

2.7K

2

Health Sciences

10

10

1.4K

3

Biochemistry

2

2

60

4

Public Health

1

1

37

5

Allergy

1

1

24

Leif Stenke

×

83

Publications

5.7K

Citations

35

H-Index

YearCitations

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn L. Slovak,

Blood

2013

621

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber,

The Lancet Oncology

2018

587

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Hagop M. Kantarjian, Andreas Hochhaus, Giuseppe Saglio,

The Lancet Oncology

2011

511

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi,

Cancer Cell

2014

363

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

Satu Mustjoki, Marja Ekblom, T. Petteri Arstila,

Leukemia

2009

316

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Mette Ilander, Ulla Olsson‐Strömberg, Heinrich Schlums,

Leukemia

2016

239

Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.

Stephen H. Petersdorf, Kenneth J. Kopecky, Robert K. Stuart,

Blood

2009

182

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Rebecca Warfvinge, Linda Geironson, Mikael N.E. Sommarin,

Blood

2017

175

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy

Anna Kreutzman, Vesa Juvonen, Veli Kairisto,

Blood

2010

170

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Martin Höglund, Fredrik Sandin, Karin Hellström,

Blood

2013

127

Page 1